Therefore, SLAMF7-expressing T cells may be good candidates for autologous cell therapy for tumor rejection, as it potentially enhances collective cell decisions to improve CD8+ T-cell responses against weak antigens. The gene discussed is CD8A; the disease is neoplasm.